The tweet was deleted by the author.
But we saved everything 🙂.
UroGen Pharma announced that its first patient has started treatment in a Phase 1 study of UGN-501 for non-muscle invasive bladder cancer. The stock is down 2.2% on the day at $32.72.
UroGen Pharma announced that the first patient has begun treatment in its Phase 1 trial testing UGN-501. The therapy is described as a next-generation investigational oncolytic virus being evaluated in non-muscle invasive bladder cancer. The company employs 300 people, operates in biotechnology, and holds a market value near $1.8 billion on trailing revenue of $188.7 million.
View post on X Loading...
The session opened with a gap down from $33.48 to $33.14, placing immediate pressure on shares of UroGen Pharma. Price is now below the MA-20 and MA-50 but remains above the MA-200, reflecting a split daily structure. The nearest support is the weekly low at $32.4. RSI at 26.1 indicates oversold conditions, which limits room for further downside after a sustained move lower with a firm trend over the past week.
To confirm whether the recent developments are being absorbed by the market, traders should watch for a close above $34.95 or a break below $32.4. Shares opened below the previous close, dropping from $33.48 to $33.14 at the start of the session. Looking ahead over the coming trading week, there is a 23% probability of upside and a 77% probability of downside, with the price expected to range between $31.57 and $33.86. Even so, a close above $34.95 would show buyers are willing to follow through, while a drop below $32.4 would show the move is being faded. On the weekly chart the longer-term picture stays constructive.
Earlier, analysts noted that UroGen Pharma's technical outlook had shifted to increased downside risk as shares hovered near key support. The initiation of the UGN-501 Phase 1 trial adds a clinical milestone, but with the price now below short-term moving averages and testing lower support, ongoing traders should watch for a decisive move below $32.4 or a close above $34.95 to gauge near-term direction.